4 Top Dividend Stocks to Buy Now
If you’re looking for steady income, dividend stocks are a…
Sell
38
NEO Quote, Financials, Valuation and Earnings
Last price:
$14.75
Seasonality move
:
23.66%
Day range:
$14.51 - $17.75
52-week range:
$12.77 - $19.12
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.90x
P/B ratio:
2.09x
Volume:
2.5M
Avg. volume:
739.8K
1-year change:
-7.51%
Market cap:
$1.9B
Revenue:
$591.6M
EPS (TTM):
-$0.61
Analysts' Opinion
-
Consensus RatingNeoGenomics has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $21.08, NeoGenomics has an estimated upside of 42.74% from its current price of $14.77.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $18.00 representing -21.87% downside risk from its current price of $14.77.
Fair Value
-
According to the consensus of 11 analysts, NeoGenomics has 42.74% upside to fair value with a price target of $21.08 per share.
NEO vs. S&P 500
-
Over the past 5 trading days, NeoGenomics has underperformed the S&P 500 by -8.66% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
NeoGenomics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
NeoGenomics has grown year-over-year revenues for 11 quarters straight. In the most recent quarter NeoGenomics reported revenues of $167.8M.
Earnings Growth
-
NeoGenomics has grown year-over-year earnings for 1 quarter straight. In the most recent quarter NeoGenomics reported earnings per share of -$0.14.
Enterprise value:
2B
EV / Invested capital:
--
Price / LTM sales:
2.90x
EV / EBIT:
--
EV / Revenue:
3.18x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-95.22x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$280.4M
Return On Assets:
-4.69%
Net Income Margin (TTM):
-12.07%
Return On Equity:
-8.38%
Return On Invested Capital:
-5.3%
Operating Margin:
-12.03%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $496.8M | $574.8M | $644.1M | $152M | $167.8M | |
| Gross Profit | $176.3M | $233.8M | $280.4M | $62.3M | $74.9M | |
| Operating Income | -$172.8M | -$101.1M | -$86.1M | -$22.1M | -$20.2M | |
| EBITDA | -$102.3M | -$24.6M | -$439K | -$1.6M | $1.8M | |
| Diluted EPS | -$1.32 | -$0.77 | -$0.61 | -$0.15 | -$0.14 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $422.4M | $709.9M | $603.4M | $587M | $590.2M | |
| Total Assets | $959.4M | $1.9B | $1.8B | $1.7B | $1.6B | |
| Current Liabilities | $64.6M | $92.7M | $85M | $92.9M | $296.4M | |
| Total Liabilities | $293.1M | $769.1M | $742.6M | $730.8M | $732.9M | |
| Total Equity | $666.4M | $1.1B | $1B | $947.4M | $908.2M | |
| Total Debt | $166.4M | $531.9M | $534.6M | $537.5M | $540.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$82.1M | -$23.4M | $15M | -$5.5M | $9.2M | |
| Cash From Investing | -$8M | $58.4M | $35.5M | $20.8M | -$3.5M | |
| Cash From Financing | $12.5M | $5.1M | $5.2M | $1.8M | $1.2M | |
| Free Cash Flow | -$120.4M | -$49.7M | -$21.5M | -$9.8M | -$1.6M | |
NEO
Sector
Market Cap
$1.9B
$47.5M
Price % of 52-Week High
77.27%
47.37%
Dividend Yield
0%
0%
Shareholder Yield
-0.32%
-0.74%
1-Year Price Total Return
-7.51%
-34.04%
Beta (5-Year)
1.239
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$17.04
200-day SMA
Sell
Level
$15.19
Bollinger Bands (100)
Sell
Level
14.28 - 17.3
Chaikin Money Flow
Buy
Level
91.5M
20-day SMA
Sell
Level
$17.14
Relative Strength Index (RSI14)
Sell
Level
36.21
ADX Line
Sell
Level
28.83
Williams %R
Buy
Level
-94.354
50-day SMA
Sell
Level
$16.51
MACD (12, 26)
Buy
Level
0.06
25-day Aroon Oscillator
Sell
Level
-4
On Balance Volume
Neutral
Level
133.5M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.998)
Buy
CA Score
(Annual)
Level (-0.2603)
Buy
Beneish M-Score
(Annual)
Level (-2.6901)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (0.202)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
Stock Forecast FAQ
In the current month, NEO has received 8 Buy ratings 3 Hold ratings, and 0 Sell ratings. The NEO average analyst price target in the past 3 months is $21.08.
-
Where Will NeoGenomics Stock Be In 1 Year?
According to analysts, the consensus estimate is that NeoGenomics share price will rise to $21.08 per share over the next 12 months.
-
What Do Analysts Say About NeoGenomics?
Analysts are divided on their view about NeoGenomics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that NeoGenomics is a Sell and believe this share price will drop from its current level to $18.00.
-
What Is NeoGenomics's Price Target?
The price target for NeoGenomics over the next 1-year time period is forecast to be $21.08 according to 11 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is NEO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for NeoGenomics is a Buy. 8 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NEO?
You can purchase shares of NeoGenomics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase NeoGenomics shares.
-
What Is The NeoGenomics Share Price Today?
NeoGenomics was last trading at $14.75 per share. This represents the most recent stock quote for NeoGenomics. Yesterday, NeoGenomics closed at $14.77 per share.
-
How To Buy NeoGenomics Stock Online?
In order to purchase NeoGenomics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Uber Stock Recover?
Shares of Uber Technologies (NYSE:UBER) have had a rough few…
Is ARK Next Generation Internet ETF a Good Investment?
The ARK Next Generation Internet ETF looks like a pretty…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
